source
- Vertex drops mRNA cystic fibrosis program over 'tolerability' issuesVertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering th…Endpoints · 2mo ago↗ source
- FDA search for new CBER head focused on small group of final candidatesThe FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three or four final candidates, according to a person familiar with the matter. The agency ho…Endpoints · 2mo ago↗ source
- Celcuity strengthens case for ASCO-spotlighted breast cancer drugThe new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.